Comments
Shares of Indian drugmaker Dr.Reddy's Laboratories plunge as much as 23 per cnet to ₹2,065.30, on the BSE, in their biggest intraday per cent loss since Oct 15, 2001
Jefferies says 11 observations under Form 483 on the company's Bachupally manufacturing unit includes four repeat observations, including one repeated from 2015 and 2017
The observations are around lack of thorough investigations, written records lacking details, employees not being trained and lack of infrastructure, said Jefferies in its report.
Jefferies cuts target price to ₹2,180 from ₹2,667.25, and retained “underperform” rating
On February 8, the company was issued Form 483 by U.S. FDA. The FDA Form 483 notifies a company's management of objectionable conditions.
Nearly 3.8 million shares changed hands, 3.7 times the 30-day average of more than 812,400
The stock posts its lowest since April 2013 and was top loser in percentage terms on the NSE index
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.